Extent and effects of recurrent shortages of purified-protein derivative tuberculin skin test antigen solutions - United States, 2013

Morbidity and Mortality Weekly Report

Volumn 62, Issue 49, 2013, Pages 1014-1015

  Turner, Rebekah E ^a   Heetderks, Andrew J ^a   Khan, Awal D ^a   Chorba, Terence L ^a   Jereb, John A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; TUBERCULIN;

HEALTH SERVICE; HUMAN; METHODOLOGY; NOTE; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PRACTICE GUIDELINES AS TOPIC; TUBERCULIN; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES;

EID: 84890336177     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. CDC. National shortage of purified-protein derivative tuberculin products. MMWR 2013;62:312.
2. CDC. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR 2010;59(No. RR-5).
3. CDC. Reported tuberculosis in the United States, 2012. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc.gov/tb/statistics/reports/2012/pdf/report2012.pdf.
4. CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6).
5. CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005;54(No. RR-17).